Abstract
Gestational trophoblastic disease (GTD) encompasses a diverse group of lesions with specific pathogenesis, morphological characteristics and clinical features. The modified World Health Organization-classification of GTD includes complete and partial hydatidiform mole, invasive mole, choriocarcinoma, placental site trophoblastic tumor, epithelioid trophoblastic tumor, exaggerated placental site, and placental site nodule. The various forms of gestational trophoblastic disease can be defined and related to discrete pathologic aberrations occurring at different stages of trophoblastic differentiation. Some of these lesions are true neoplasms, whereas others represent abnormally formed placentas with a predisposition for neoplastic transformation of the trophoblast. Except hydatidiform moles in which the cytogenetic studies have been extensively reported, the pathogenesis of other trophoblastic lesions is poorly understood. Recent studies have shed light on the molecular mechanisms of trophoblastic func tion, especially as it relates to trophoblastic disease. This review will focus on these advances with special emphasis on the pathogenesis of each specific form of GTD. In addition, the morphology and clinical behavior of each of these entities will be briefly discussed.
Keywords: Gestational Trophoblastic Diseases, Human trophoblast, Syncytiotrophoblast, Choriocarcinoma, Placental site trophoblastic pstt, Epithelioid trophoblastic tumor, Exaggerated placental site eps
Current Molecular Medicine
Title: Molecular Basis of Gestational Trophoblastic Diseases
Volume: 2 Issue: 1
Author(s): Le-ming Shih and Robert J. Kurman
Affiliation:
Keywords: Gestational Trophoblastic Diseases, Human trophoblast, Syncytiotrophoblast, Choriocarcinoma, Placental site trophoblastic pstt, Epithelioid trophoblastic tumor, Exaggerated placental site eps
Abstract: Gestational trophoblastic disease (GTD) encompasses a diverse group of lesions with specific pathogenesis, morphological characteristics and clinical features. The modified World Health Organization-classification of GTD includes complete and partial hydatidiform mole, invasive mole, choriocarcinoma, placental site trophoblastic tumor, epithelioid trophoblastic tumor, exaggerated placental site, and placental site nodule. The various forms of gestational trophoblastic disease can be defined and related to discrete pathologic aberrations occurring at different stages of trophoblastic differentiation. Some of these lesions are true neoplasms, whereas others represent abnormally formed placentas with a predisposition for neoplastic transformation of the trophoblast. Except hydatidiform moles in which the cytogenetic studies have been extensively reported, the pathogenesis of other trophoblastic lesions is poorly understood. Recent studies have shed light on the molecular mechanisms of trophoblastic func tion, especially as it relates to trophoblastic disease. This review will focus on these advances with special emphasis on the pathogenesis of each specific form of GTD. In addition, the morphology and clinical behavior of each of these entities will be briefly discussed.
Export Options
About this article
Cite this article as:
Shih Le-ming and Kurman J. Robert, Molecular Basis of Gestational Trophoblastic Diseases, Current Molecular Medicine 2002; 2 (1) . https://dx.doi.org/10.2174/1566524023362960
DOI https://dx.doi.org/10.2174/1566524023362960 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Impact of Curcumin on Microsomal Enzyme Activities: Drug Interaction and Chemopreventive Studies
Current Medicinal Chemistry Management of Ovarian Cancer In Younger Women
Reviews on Recent Clinical Trials Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets Gonadotropin-Releasing Hormone Receptor Signaling: Biased and Unbiased
Mini-Reviews in Medicinal Chemistry Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
Current Molecular Pharmacology HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) Immune Function in Pregnant Women with Affective Disorders
Current Psychiatry Reviews Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Unravelling the Role of Infectious Agents in the Pathogenesis of Human Autoimmunity: The Hypothesis of the Retroviral Involvement Revisited
Current Molecular Medicine Gonadotropin-Releasing Hormone (GnRH) Receptors in Tumors: a New Rationale for the Therapeutical Application of GnRH Analogs in Cancer Patients?
Current Cancer Drug Targets Placental Growth Hormone, Fetal Growth and the IGF Axis in Normal and Diabetic Pregnancy
Current Diabetes Reviews Iron Oxide Nanoparticles: An Insight into their Biomedical Applications
Current Medicinal Chemistry From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Functional Role of miR-34 Family in Human Cancer
Current Drug Targets Modified Envelope Glycoproteins to Retarget Retroviral Vectors
Current Gene Therapy DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design Suppressing Glioblastoma Stem Cell Function by Aldehyde Dehydrogenase Inhibition with Chloramphenicol or Disulfiram as a New Treatment Adjunct: A Hypothesis
Current Stem Cell Research & Therapy